阿斯利康攜重磅研究，創(chuàng)連續(xù)七年亮相美國臨床腫瘤學(xué)會(ASCO)全體大會紀錄，進一步彰顯重新定義乳腺癌治療和改變胃癌治療結(jié)局的雄心

阿斯利康

2025-05-22 16:54 8387

SERENA-6 研究的全體大會報告將聚焦用于晚期 HR 陽性乳腺癌一線治療的新一代口服 SERD 藥物 Camizestrant

MATTERHORN 研究的全體大會報告將展示英飛凡用于早期胃和胃食管結(jié)合部腺癌的圍手術(shù)期治療方案

DESTINY-Breast09 研究的專場口頭報告將強調(diào)優(yōu)赫得在 HER2 陽性轉(zhuǎn)移性乳腺癌更前線治療的潛力

上海 2025年5月22日 /美通社/ -- 阿斯利康在2025年5月30日至6月3日召開的美國臨床腫瘤學(xué)會（ASCO）上，憑借行業(yè)領(lǐng)先的多樣化產(chǎn)品與管線布局的全新研究數(shù)據(jù)，進一步深化自身讓癌癥不再成為致死主因的雄心。

會上將有超過80個摘要公布，其中涵蓋20款已獲得批準的藥物和潛在新藥，包括兩項重磅研究的全體大會報告（plenary presentation），一項特別重磅研究摘要口頭報告（late-breaking oral abstract session），以及19項口頭報告。其中亮點包括：

SERENA-6 ：評估了Camizestrant與廣泛獲批的細胞周期蛋白依賴性激酶（CDK）4/6抑制劑聯(lián)合，用于一線治療激素受體（HR）陽性、HER2陰性且腫瘤出現(xiàn)ESR1突變的晚期乳腺癌患者的III期臨床研究（Plenary #LBA4）。Camizestrant是在研的新一代選擇性雌激素受體降解劑（SERD）和完全ER拮抗劑。這是首個在一線治療中取得陽性結(jié)果的新一代口服SERD藥物III期臨床研究，也是Camizestrant的首個III期陽性結(jié)果。
MATTERHORN：評估了度伐利尤單抗聯(lián)合FLOT化療作為可切除的早期和局部晚期的胃和胃食管結(jié)合部腺癌（GEJ）患者圍手術(shù)期治療方案的III期研究（Plenary #LBA5）。
DESTINY-Breast09：評估德曲妥珠單抗聯(lián)合帕妥珠單抗用于一線治療HER2陽性轉(zhuǎn)移性乳腺癌患者治療獲益的III期研究（口頭報告摘要#LBA1008）。
DESTINY-Gastric04 ：評估了德曲妥珠單抗用于二線治療HER2陽性不可切除和/或轉(zhuǎn)移性胃和胃食管結(jié)合部腺癌患者的治療獲益的III期研究（#LBA4002）。
NeoADAURA：奧希替尼聯(lián)合或不聯(lián)合化療作為新輔助治療用于可切除的早期EGFR突變非小細胞肺癌（NSCLC）的III期臨床研究（口頭報告摘要#8001）。
TROPION-Lung02：Datroway聯(lián)合帕博利珠單抗的聯(lián)合或不聯(lián)合鉑類一線化療治療無驅(qū)動基因突變的晚期非小細胞肺癌的Ib期臨床研究結(jié)果，基于計算病理學(xué)生物標志物分析（口頭報告摘要#8501）。
KOMET：評估司美替尼治療伴有癥狀性、無法手術(shù)的叢狀神經(jīng)纖維瘤的1型神經(jīng)纖維瘤病成人患者的III期臨床研究（快速口頭摘要#3014）。

阿斯利康全球執(zhí)行副總裁、全球腫瘤研發(fā)負責(zé)人高書璨（ Susan Galbraith）表示："本次ASCO大會上公布的兩項乳腺癌重磅研究數(shù)據(jù)將凸顯我們在以創(chuàng)新藥物和產(chǎn)品管線改變腫瘤治療結(jié)局上所取得的進展。SERENA-6是首個采用循環(huán)腫瘤DNA檢測指導(dǎo)治療方案切換的一項關(guān)鍵III期臨床研究，開創(chuàng)了這一技術(shù)在一線治療中的應(yīng)用，以延緩HR陽性、HER2陰性晚期乳腺癌的疾病進展。此外，DESTINY-Breast09研究評估了德曲妥珠單抗與帕妥珠單抗的聯(lián)合治療方案，這是十年來首次在HER2陽性轉(zhuǎn)移性乳腺癌廣泛患者群體中，證明療效優(yōu)于目前一線治療標準方案的試驗。"

阿斯利康全球執(zhí)行副總裁，全球腫瘤研發(fā)負責(zé)人Dave Fredrickson表示："MATTERHORN的研究數(shù)據(jù)證明，度伐利尤單抗作為胃和胃食管結(jié)合部腺癌患者圍手術(shù)期的治療方案，是我們將免疫療法遷入癌癥早期階段治療的成功例證，有望實現(xiàn)早期治愈的可能。這是阿斯利康連續(xù)第七年登上ASCO全體大會，這一非凡的里程碑彰顯出我們在多個癌腫領(lǐng)域已建立行業(yè)領(lǐng)先的腫瘤產(chǎn)品組合和強大的研發(fā)管線。

阿斯利康與第一三共聯(lián)合開發(fā)和商業(yè)化德曲妥珠單抗與Datroway；與默沙東（默沙東是美國新澤西州羅威市默克公司的公司商號）聯(lián)合開發(fā)和商業(yè)化司美替尼；與和黃醫(yī)藥合作開發(fā)和商業(yè)化賽沃替尼。

阿斯利康在 2025 年 ASCO 大會期間的重要演講 ¹

主要作者

摘要標題

演示文稿詳情 (CDT)

抗體偶聯(lián)藥物

Shitara, K

Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study.

Abstract #LBA4002

Oral Abstract Session

31 May 2025

3:24pm

Tolaney, SM

Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09.

Abstract #LBA1008

Oral Abstract Session

2 June 2025

7:30am

Dent, R

Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06).

Abstract #1013

Oral Abstract Session

31 May 2025

3:23pm

Levy, BP

TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC).

Abstract #8501

Oral Abstract Session

1 June 2025

8:12am

Waqar, SN

First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5).

Abstract #8521

Poster Session

31 May 2025

1:30pm

腫瘤驅(qū)動因素和耐藥性

Turner, NC

Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial.

Abstract #LBA4

Plenary Session

1 June 2025

2:41pm

Lu, S

Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study.

Abstract #LBA8505

Oral Abstract Session

1 June 2025

9:48am

Levy, BP

Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO).

Abstract #8513

Rapid Oral Abstract Session

2 June 2025

8:06am

Chaft JE

Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA.

Abstract #8001

Oral Abstract Session

2 June 2025

3:12pm

免疫腫瘤學(xué)與雙特異性抗體

Janjigian, YY

Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC).

Abstract #LBA5

Plenary Session

1 June 2025

3:13pm

Powles, T

Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA

Abstract #4503

Oral Abstract Session

1 June 2025

10:45am

Reck, M

Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial.

Abstract #8009

Rapid Oral Abstract Session

1 June 2025

4:30pm

Barbie, DA

Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC).

Abstract #8014

Rapid Oral Abstract Session

1 June 2025

5:12pm

Mayadev, J

Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses.

Abstract #5502

Oral Abstract Session

2 June 2025

8:48am

Westin, SN

Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA.

Abstract #5512

Rapid Oral Abstract Session

3 June 2025

8:30am

Erinjeri, JP

Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC).

Abstract #4083
Poster Session

31 May 2025

9:00am

Cascone, T

Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2.

Abstract #8046

Poster Session

31 May 2025

1:30pm

Zhou, J

First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A.

Abstract #4080

Poster Session

31 May 2025

9:00am

Xu, R

ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC).

Abstract #TPS4204

Poster Session

31 May 2025

9:00am

Mathias, C

ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1.

Abstract #TPS8653

Poster Session

31 May 2025

1:30pm

細胞療法

Yoo, C

RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC).

Abstract #TPS4215

Poster Session

31 May 2025

9:00am

Kim, TM

Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma.

Abstract #7046
Poster Session

1 June 2025

9:00am

Shadman, M

TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies.

Abstract #TPS7091

Poster Session

1 June 2025

9:00am

Le Gouill, S

SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies.

Abstract #TPS7083

Poster Session

1 June 2025

9:00am

罕見病藥物

Chen, AP

Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study.

Abstract #3014

Rapid Oral Abstract Session

2 June 2025

8:00am

¹ 阿斯利康在2025年ASCO大會將公布超過80個摘要，涵蓋其產(chǎn)品和管線中的分子藥物

關(guān)于阿斯利康腫瘤領(lǐng)域的研究

阿斯利康正引領(lǐng)著腫瘤領(lǐng)域的一場革命，致力提供多元化的腫瘤治療方案，以科學(xué)探索腫瘤領(lǐng)域的復(fù)雜性，發(fā)現(xiàn)、研發(fā)并向患者提供改變生命的藥物。

阿斯利康專注于最具挑戰(zhàn)性的腫瘤疾病，通過持續(xù)不斷的創(chuàng)新，阿斯利康已經(jīng)建立了行業(yè)領(lǐng)先的多元化的產(chǎn)品組合和管線，持續(xù)推動醫(yī)療實踐變革，改變患者體驗。

阿斯利康以期重新定義癌癥治療并在未來攻克癌癥。

關(guān)于阿斯利康

阿斯利康（LSE/STO/Nasdaq: AZN）是一家科學(xué)至上的全球生物制藥企業(yè)，專注于研發(fā)、生產(chǎn)及營銷處方類藥品，重點關(guān)注腫瘤、罕見病以及包括心血管腎臟及代謝、呼吸及免疫在內(nèi)的生物制藥等領(lǐng)域。阿斯利康全球總部位于英國劍橋，業(yè)務(wù)遍布超過125個國家，創(chuàng)新藥物惠及全球數(shù)百萬患者。更多信息，請訪問www.astrazeneca.com。

關(guān)于阿斯利康中國

阿斯利康自1993年進入中國以來，專注中國患者需求最迫切的治療領(lǐng)域，包括腫瘤、心血管、腎臟、代謝、呼吸、消化、罕見病、疫苗抗體及自體免疫等，已將40多款創(chuàng)新藥物帶到中國。阿斯利康中國總部位于上海，并在上海和北京設(shè)立全球戰(zhàn)略研發(fā)中心，在北京、廣州、杭州、成都、青島設(shè)立區(qū)域總部，在無錫、泰州、青島建立全球生產(chǎn)供應(yīng)基地，向全球70多個市場輸送優(yōu)質(zhì)創(chuàng)新藥品。

聲明：本文研究中涉及的多種藥品用法尚未在中國獲批適應(yīng)癥，阿斯利康不推薦任何未被批準的藥品使用。

消息來源：阿斯利康

相關(guān)股票：

LSE:AZN NASDAQ:AZN